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Abstract Endocannabinoids, including anandamide (AEA),
have been implicated in neuroprotective on-demand
responses. Related to such a response to injury, an excitotoxic
kainic acid (KA) injection (i.p.) was found to increase AEA
levels in the brain. To modulate the endocannabinoid response
during events of excitotoxicity in vitro and in vivo, we utilized
a new generation compound (AM5206) that selectively
inhibits the AEA deactivating enzyme fatty acid amide
hydrolase (FAAH). KA caused calpain-mediated spectrin
breakdown, declines in synaptic markers, and disruption of
neuronal integrity in cultured hippocampal slices. FAAH
inhibition with AM5206 protected against the neurodegener-
ative cascade assessed in the slice model 24 h postinsult. In
vivo, KA administration induced seizures and the same
neurodegenerative events exhibited in vitro. When AM5206
was injected immediately after KA in rats, the seizure scores
were markedly reduced as were levels of cytoskeletal damage
and synaptic protein decline. The pre- and postsynaptic
proteins were protected by the FAAH inhibitor to levels
comparable to those found in healthy control brains. These
data support the idea that endocannabinoids are released and
converge on pro-survival pathways that prevent excitotoxic
progression.
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Introduction
The endogenous cannabinoid system is involved in a
myriad of physiological processes, including nociception,
memory, feeding behavior, lipid metabolism, and gastroin-
testinal motility (Rodriguez de Fonseca et al. 2005; Viveros
et al. 2008; Kunos et al. 2009; Izzo and Sharkey 2010). The
endocannabinoids anandamide (AEA) and 2-arachidonoyl
glycerol (2-AG) have also been linked to on-demand
responses that protect against seizure damage, stroke/
ischemia, traumatic brain injury, and multiple sclerosis
(see reviews, Bahr et al. 2006; Fernandez-Ruiz et al. 2010;
Hwang et al. 2010; Sagar et al. 2010). The endocannabi-
noids may mediate their protective effects through several
pathways linked to CB1 receptors, including triggering
potassium channel opening, inhibition of calcium currents,
and eliciting signaling element responses for neuronal
maintenance (Deadwyler et al. 1995; Gomez del Pulgar et
al. 2000; Galve-Roperh et al. 2002; Karanian et al. 2005b,
2007; Molina-Holgado et al. 2005). Correspondingly,
activated CB1 receptors have been reported to reduce
neurotransmitter release and in turn, suppress excitability
and potential excitotoxic progression (Hajos et al. 2000;
Kreitzer and Regehr 2001; Ohno-Shosaku et al. 2001;
Wilson et al. 2001). From the many studies, promoting
cannabinoid responses is being pursued as a protection
strategy. Blocking endocannabinoid inactivation mecha-
nisms, in particular, is an ideal target for neuroprotective
modulation of cannabinergic signaling.
Enhanced cannabinoid signaling can be achieved by
preventing AEA hydrolysis/inactivation by fatty acid amide
hydrolase (FAAH). FAAH is highly expressed by neurons in
the rat hippocampus, neocortex, and cerebellum (Egertova et
al. 1998), and is responsible for degrading AEA after its
release from neurons (Basavarajappa 2007; Di Marzo 2008).
Studies with FAAH inhibitors and FAAH-knockout mice
have described the outcome of elevated signaling through
CB1 receptors (Cravatt et al. 2001; Kathuria et al. 2003;
Karanian et al. 2005b, 2007). Targeted FAAH inhibition
successfully enhances endocannabinoid signaling in the
hippocampus, mediated predominantly via CB1 receptors
(Deadwyler et al. 1993; Onaivi 2009). It has also been
suggested in different animal models of epilepsy that high
concentrations of CB1 receptors in the hippocampal forma-
tion reduce seizure activity by protecting neurons against
excessive glutamatergic activity (Arida et al. 2005; Araujo et
al. 2010). These findings suggest a key role played by
endocannabinoids in excitotoxic protection.
FAAH inhibition is a potential avenue for the attenuation of
neural overexcitation and excitotoxic progression (Cippitelli
et al. 2008; Janero et al. 2009; Straiker and Mackie 2009).
Several studies have documented the neuroprotective capa-
bilities of FAAH inhibitors, showing reduced hippocampal
excitability (Coomber et al. 2008) and seizure severity
(Karanian et al. 2005b, 2007). FAAH inhibitors are
particularly advantageous to promote CB1 signaling without
the adverse psychotropic effects usually associated with
direct activation of the CB1 receptor (Karanian et al. 2007;
Janero et al. 2009). In the present study, we investigated the
neuroprotective effects of the new generation, reversible
FAAH inhibitor AM5206 in vitro and in vivo. Our results
indicate that after excitotoxic insults, FAAH inhibition with
AM5206 protects against neural compromise in hippocampal
slices and reduces seizure activity and seizure-associated
damage in rats.
Materials and Methods
Animals
Animal use protocols were approved by the Institutional
Animal Care and Use Committees of the University of
Connecticut and the University of North Carolina Pembroke.
Groups of male rats for in vivo work and litters of rat pups (11
to 12 days postnatal) for hippocampal slice work were
obtained from Charles River Laboratories (Wilmington,
MA). The animals were housed according to guidelines from
the National Institutes of Health and had food and water
available ad libitum.
Chemicals and Antibodies
The reversible FAAH inhibitor was synthesized following a
distinct reaction pathway to make the trifluoromethylketo-
phenoxypentyl analog AM5206. Kainic acid (KA) was
obtained from Tocris (Ellisville, MO). Affinity purification
of antibodies to the calpain-mediated spectrin fragment BDPN
and to α-amino-3-hydroxy-5-methyl-4-isoxazolepropionate
(AMPA) receptor subunit glutamate receptor 1 (GluR1, also
referred to as GluA1 or GluR-A) was conducted using
previously described methods (Bahr 1995; Bahr et al. 2002).
Anti-synapsin II was purchased from CalbioChem (San
Diego, CA) and anti-actin from Sigma (St. Louis, MO). All
other reagents were from Sigma.
FAAH and MAGL Fluorometric Assays
Recombinant rat FAAH and recombinant hexa-histidine-
tagged human monoacylglycerol lipase (MAGL) were
expressed in E. coli as previously described (Patricelli et
al. 1998; Ramarao et al. 2005; Zvonok et al. 2008). FAAH
and MAGL activities were performed in 96-well plates
using the fluorogenic substrates arachidonoyl 7-amino-4-
methylcoumarin amide for FAAH, and arachidonoyl,
7-hydroxy-6-methoxy-4-methylcoumarin ester for MAGL.
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Fluorescence was recorded in 20-min intervals at emission
wavelengths of 460 nm. Concentration–response curves
across increasing concentrations of AM5206 (Graphpad
Prism, San Diego, CA), and IC50 values were determined.
Endocannabinoid and AM5206 Detection
Sprague–Dawley rats were injected i.p. with phosphate-
buffered saline (PBS), 9.5 mg/kg KA, or 60 mg/kg AM5206.
After 2–3 h, the cortex and other tissues were rapidly dissected,
flash-frozen and stored at −80°C. From the samples, protein
content was precipitated with ice-cold acetone, followed by
liquid–liquid phase extraction of endocannabinoids or
AM5206 using methanol and chloroform. For endocannabi-
noid analysis, subsequent liquid chromatography-mass spec-
trometry analyses were conducted as previously described
(Williams et al. 2007; Wood et al. 2008; 2010). Chromato-
graphic separation was achieved using an Agilent Zorbax SB-
CN column (2.1×50 mm) on a Finnigan TSQ Quantum Ultra
triple quad mass spectrometer (Thermo Electron Corporation,
Waltham, MA) with an Agilent 1100 HPLC on the front end
(Agilent Technologies, Palo Alto, CA) in positive APCI
mode. The mobile phase consisted of 10 mM ammonium
acetate (pH 7.3) and methanol. AM5206 levels were assessed
as eluted from a Phenomenex Gemini C18 column (2×
50 mm, 5 μm pore size) with a C18 guard column, using
0.1% formic acid in water and 0.1% formic acid in methanol,
ionized with negative electrospray ionization, and detected in
selected reaction monitoring mode.
Organotypic Hippocampal Slice Cultures
Brain tissue from 11- to 12-day-old postnatal Sprague–
Dawley rat pups was rapidly removed to prepare slices as
previously described (Bahr 1995; Karanian et al. 2005b,
2007). Transverse slices of hippocampus (400 μm) were
prepared and placed on Millicell-CM insert membranes
(Millipore Corporation, Bedford, MA) with culture medium
consisting of 50% basal medium Eagle, 25% Earle’s
balanced salts, 25% horse serum, and defined supplements
(Bahr et al. 1994). The slices were maintained in culture at
37°C in 5% CO2-enriched atmosphere for a 15–20-day
maturation period before experimental use.
Model of Excitotoxicity in Slice Cultures
Cultured hippocampal slices were pretreated for 60 min
with serum-free media plus 0.1% DMSO, in the absence of
presence of 10–30 μM AM5206. The media was aspirated
and the wells washed once with fresh medium. Slices were
subsequently treated with vehicle or 60 μM KA for 2 h in
the absence or presence of 10–30 μM of AM5206. The
media was then removed, and the slices washed and
incubated with or without AM5206 for 24 h. At that time,
the slices were harvested for histology and immunoblotting.
Histology
Cultured hippocampal slices were fixed in formalin overnight
at 4°C, incubated in PBS, and mounted onto Superfrost slides
(Fisher Scientific, Pittsburgh, PA) for Nissl staining.
Immunoblot Analysis
Groups of six to eight hippocampal slices each were
harvested with a soft brush in ice-cold harvest buffer
composed of 0.32 M sucrose, 5 mM HEPES (pH 7.5),
1 mM ethylenediaminetetraacetic acid (EDTA), 1 mM
ethylene glycol tetraacetic acid (EGTA), and the protease
inhibitors antipain, 4-(2-aminoethyl) benzenesulfonyl fluo-
ride, pepstatin A, E-64, bestatin, leupeptin, and aprotinin
(2 μg/ml each). The slices were sonicated in lysis buffer of
6 mM Tris (pH 8.1), 0.2 mM EDTA, 0.2 mM EGTA, and
protease inhibitors. Protein content was determined in the
homogenized samples with a bovine serum albumin
standard. Aliquots (75 μg) of the protein samples were
denatured in SDS at 100°C, separated by electrophoresis on
4–15% SDS-PAGE, and then blotted to nitrocellulose.
Immunodetection used antibodies against calpain-mediated
spectrin BDPN, synapsin II, the AMPA receptor subunit
GluR1, and the protein load control actin. Anti-IgG-alkaline
phosphatase conjugates were used for secondary antibody
incubation. Development of immunoreactive species used
the 5-bromo-4-chloro-3-indolyl phosphate and nitroblue
tetrazolium substrate system and was terminated prior to
maximum intensity in order to avoid saturation. Integrated
optical density of the bands was determined with image
analysis at high resolution with BIOQUANTsoftware (R&M
Biometrics; Nashville, TN). Mean integrated densities for
various antigens are expressed as mean values ± SEM.
Lactate Dehydrogenase Assay
Lactate dehydrogenase (LDH) activity in the culture medium
was measured using the Cytotox 96 Non-Radioactive Cyto-
toxicity Kit (Promega, Madison, WI). Thirty microliters of
media were transferred to wells of a 96-well plate in triplicate,
mixed with assay reagent and allowed to react for 30 min.
Stop solution was then added to each well and absorbances
immediately recorded at 490 nm using a Molecular Devices
Plate Reader (Sunnyvale, CA).
Model of Excitotoxicity in Vivo
Sprague–Dawley rats were injected i.p. with PBS or
9 mg/kg KA. Immediately following the KA injection,
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the rats were administered a subsequent injection (i.p.) with
either vehicle or 8 mg/kg AM5206. The animals were then
monitored and scored for seizure activity (see below) by
observers blinded to the treatment groups. At 48 h postinjec-
tion, brains were rapidly removed with ice-cold buffer
containing a protease inhibitor cocktail. Hippocampi were
homogenized in lysis buffer with protease inhibitors. Protein
content was determined and samples assessed for BDPN,
GluR1, and synapsin II.
Seizure Scoring
For the excitotoxicity study, animals were observed for 4 h
following injections. The seizure score was recorded every
15 min, representative of the seizure expression during that
period. The seizure rating scale consisted of the following
seven stages: stage 0, normal behavior; stage 1, freezing,
staring, or mouth/facial movements; stage 2, rigid posture,
head nodding or isolated twitches; stage 3, tail extension,
unilateral–bilateral forelimb clonus, or repetitive scratching;
stage 4, rearing with one or both forepaws extended; stage 5,
clonic seizures with loss of posture, jumping, and falling;
stage 6, severe tonic seizures.
Plasma Analysis
Trunk blood from rats treated with AM5206 was collected
in heparinized tubes, centrifuged at 5,000 rpm for 5 min
and the plasma drawn off for analyses. Alanine amino-
transferase (ALT) activity was measured with Infinity ALT
Liquid Stable reagent, and blood urea nitrogen (BUN)
levels were assessed using Infinity Urea Liquid Stable
reagent (Thermotrace, Melbourne, Australia).
Statistical Analyses
Data were analyzed using unpaired t tests or one-way
ANOVA followed by the Tukey’s post hoc tests.
Results
We monitored the endocannabinoid response in rats injected
with an excitotoxic level of KA (9.5 mg/kg). Mass spectrom-
etry was used to test whether enhancement of brain AEA levels
occurred in the KA-treated animals (Fig. 1b) as compared to
control rats (Fig. 1a). A 2.7-fold increase in AEAwas evident
in the cortical samples from KA rats (n=6; Fig. 1c). No
change in AEA was evident in plasma samples after the KA
treatment (96±15% of vehicle-injected controls) nor in
mesencephalic tissue (92±8% of control) or hindbrain (87±
13%). KA also increased cortical 2-AG levels from 91,320±
7,020 to 362,200±45,140 ng/g (mean ± SEM; P<0.0001),
without any change in plasma 2-AG levels (28.1±1.6 ng/μl
in vehicle rats; 26.2±2.7 ng/μl in KA rats). Thus, as
previously reported, the on-demand cannabinergic response
after an excitotoxic insult elevates endocannabinoid levels in
the brain (Hansen et al. 2001; Marsicano et al. 2003;
Karanian et al. 2007).
To test whether FAAH inhibition promotes the protective
nature of the endocannabinoid system, we used the new
generation FAAH inhibitor AM5206. In separate FAAH and
MAGL assays, AM5206 caused a concentration-dependent
inhibition of both activities, but more potently inhibited FAAH
over MAGL (Fig. 2). Similar results were found across three
separate experiments, with AM5206 being 280- to 480-fold
Fig. 1 Exposure to the excitotoxin KA increases AEA levels in the
brain. Vehicle (a) or 9.5 mg/kg KA (b) was systemically administered
to rats. At the 2 h postinjection time, cortical tissue was rapidly
dissected, flash-frozen in liquid nitrogen, and assayed for AEA levels
by mass spectrometry as described in the “Materials and Methods”
section. Time of elution (minutes) from the reverse phase column is
represented by the X-axes and is noted for reference peaks and AEA
(shaded). AEA levels (nanograms per gram of wet tissue weight) were
determined using an AEA standard curve and means ± SEM are
shown (c). Unpaired t test; triple asterisk, P<0.001
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more selective for FAAH (42±6 nM, IC50±SD) compared to
MAGL (15,130±2,800 nM).
Next, we tested AM5206 for its neuroprotective ability
by assessing the cellular and molecular events of excitotox-
icity in the hippocampal slice model (Vanderklish and Bahr
2000; Bahr et al. 2002; Karanian et al. 2005b). Histological
analysis of cellular integrity was performed by Nissl stain,
showing that slice cultures possess native neuronal organi-
zation of hippocampal subfields (Fig. 3a). Compared to
vehicle-treated slices (Fig. 3b), neurons of the KA-treated
tissue showed pronounced pyknotic changes with a severe
loss of pyramidal neurons (Fig. 3c). AM5206 protected
against KA-induced neurodegeneration by preserving neu-
ronal structure, as confirmed by an absence of pathogenic
manifestations (Fig. 3d).
For further detection of excitotoxic neurodegeneration in
the rat hippocampus, we immunoblotted the slice samples
to assess BDPN, a marker of cytoskeletal breakdown, and
for the synaptic proteins synapsin II and AMPA-R subunit
glutamate receptor 1 (GluR1; also referred to as GluA1 or
GluR-A). The excitotoxic insult caused the characteristic
production of N-terminal spectrin breakdown product
BDPN mediated by calpain and a corresponding loss of
synaptic components (Fig. 4a). The neuroprotective poten-
tial of AM5206 is evidenced by the nearly complete
elimination of BDPN 24 h postinsult (Fig. 4b). In addition,
the postsynaptic marker GluR1 exhibited significant pro-
tection by the FAAH inhibitor (Fig. 4a, c), and similar
results were found concerning the presynaptic synapsin II
(see Fig. 4a). Assessment of LDH released from damaged
neurons into the media also indicated significant cellular
protection by AM5206 (Fig. 4d). The FAAH inhibitor
treatment lowered KA-induced LDH levels by 60%.
Extending the work from the in vitro slice model
required assessment of AM5206 in the intact animal. To
first confirm that AM5206 crosses the blood–brain barrier,
a high level of AM5206 (60 mg/kg) was injected i.p. into
rats and was subsequently detected in the cortex at a
concentration of 2–6 ng per gram of brain tissue at 2 h
postinjection. After 3 h, AM5206 was still detected in the
cortex (0.25–0.73 ng/g) as well as in the hippocampus
(0.39–1.3 ng/g). The average plasma level that AM5206
reached was 27.1±3.9 ng/μl (n=6 rats). As evidence that
the FAAH inhibitor modulated the endocannabinoid sys-
tem, the baseline AEA to 2-AG ratio (1.6±0.14) was
increased 44% in the AM5206 animals to 2.3±0.15 (n=8;
P<0.01).
To further evaluate neuroprotection in vivo, we tested
whether AM5206 injected i.p. into rats provided protection
against KA-induced seizures. For the work with the
Fig. 2 AM5206 selectively inhibits FAAH activity. Recombinant
FAAH and MAGL were treated with varying concentrations of
AM5206 in triplicate, and the two hydrolytic activities were
determined using specific fluorogenic substrates. Data were normalized
to 100% fluorescence activity in the absence of drug and are presented as
means ± SEM
Fig. 3 AM5206 affords neuronal protection in the hippocampus after
KA-induced excitotoxicity in vitro. Organotypic hippocampal slice
cultures were used, and a low-power photomicrograph shows their
characteristic maintenance of native cellular organization (a). Nissl
staining was also used to assess cellular integrity across treatment
groups. CA3 pyramidal zones are shown from slices treated consistently
with vehicle (b), those pretreated with vehicle before a 2-h exposure to
60 μM KA (c), and slices pretreated with 10 μM AM5206 before the
KA insult (d). After a washout step, the cultured slices were then
incubated with vehicle or AM5206 for 24 h before the tissue was fixed,
sectioned, and stained. The KA insult resulted in neuronal loss and
obvious pyknotic changes that were reduced by the FAAH inhibitor.
DG, dentate gyrus; so, stratum oriens; sp, stratum pyramidale; sr,
stratum radiatum. Scale bar: a, 400 μm; b–d, 45 μm
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excitotoxic rat model, the study included three treatment
groups of animals: (1) those that received two vehicle i.p.
injections, (2) those that received KA (9.5 mg/kg) followed
by an immediate vehicle injection, or (3) those that received
KA followed immediately by an injection of 8 mg/kg
AM5206. Seizures were scored, and AM5206 demonstrated
a 79% reduction in seizure severity compared to animals
that only received vehicle after the KA treatment (ANOVA,
P<0.0001) (Fig. 5a). To determine if a correspondence
exists between seizure protection and molecular indicators
of excitotoxicity, hippocampi were removed from the three
treatment groups and immunoblotted against BDPN,
GluR1, and synapsin II. The hippocampal samples from
KA alone animals showed strong immunoreactivity for
BDPN, and this was associated with a decline in GluR1 and
synapsin II (Fig. 5b). Hippocampi from rats treated with
KA and AM5206, however, showed reduced BDPN
immunoreactivity and preserved staining for the synaptic
markers (see Fig. 5b, c). Thus, systemically administered
AM5206 attenuates seizure severity and elicits cytoskeletal
and synaptic protection.
Finally, AM5206 was evaluated to provide an initial
safety assessment. Sprague–Dawley rats were injected i.p.
daily for 14 days with 0–15 mg/kg AM5206, thus covering
a dosage range above that used for neuroprotection. Across
the 14-day period, no obvious behavioral abnormalities
were observed, including seizure events. In the AM5206
rats, scores given on treatment days 12–14 remained at the
typical low baseline level characteristic of vehicle-treated
controls (Fig. 6a). Mean scores from the three treatment
groups were not different than zero according to one-sample t
Fig. 4 Treatment with AM5206
elicits several indicators of neu-
roprotection in the hippocampal
slice model. The slices were
treated consistently with vehicle
(veh), pretreated with vehicle
before a 2-h KA exposure, or
pretreated with AM5206 before
the KA insult. After the KA
exposure and a washout step,
slices were returned to their
prior condition of the absence or
presence of AM5206. Slices
were harvested 24 h postinsult
in groups of six to eight and
assessed by immunoblotting for
calpain-mediated spectrin break-
down product BDPN, synaptic
markers GluR1 and synapsin II
(syn II), and protein load control
actin (see blots in a). Integrated
optical densities for BDPN (b)
and GluR1 (c) across the treat-
ment groups are compared as
means ± SEM. Unpaired t test
compared to KA+vehicle data,
single asterisk P<0.05; double
asterisk P<0.01. Treated slices
(25–27 per condition) divided
into three groups were also
assessed for LDH activity
released into the culture medium
(d). LDH release is expressed as
the colorimetric assay absorbance
(mean ± SEM) corrected for
background activity present in
fresh medium. AM5206 effect:
single asterisk, P=0.026
Fig. 5 AM5206 affords seizure and neuronal protection after KA-
induced excitotoxicity in vivo. Seizures were induced by i.p. injection of
9.5 mg/kg KA (n=12 rats), and following the KA administration animals
were immediately injected with either vehicle or 8 mg/kg AM5206.
Vehicle-treated control rats (veh, n=11) did not receive KA or AM5206.
Seizures were scored by blinded raters over a 4-h period (a) and mean
scores ± SEM are shown (ANOVA, P<0.0001). At 48 h postinjection,
hippocampal tissue was rapidly dissected, homogenized, and equal
protein aliquots assessed by immunoblot for BDPN, GluR1, synapsin II
(syn II), and actin (b). Mean integrated optical densities for GluR1 (c) are
shown (±SEM; ANOVA, P<0.001). Post hoc tests compared to KA+
vehicle data, single asterisk P<0.05; triple asterisk, P<0.001
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tests. In plasma samples collected from the same animals,
ALT activity (Fig. 6b) and BUN levels (Fig. 6c) were also
unchanged by the repeated administration of AM5206.
Injecting a hepatotoxin to induce organ toxicity, such
positive-control rats indeed exhibited much elevated ALT
activity (280±50 U/L) and BUN (130±14 mg/dl) levels in
plasma samples. These initial safety results show that the
FAAH inhibitor AM5206 does not cause adverse effects on
behavior or major organ functions.
Discussion
Substantial evidence indicates that the endocannabinoid
system plays a protective role against excitotoxic events linked
to seizure activity and associated neurodegeneration. The
proconvulsant KA was found to increase cortical AEA in the
present study, adding to the evidence that endocannabinoid
levels are elevated as part of internal repair responses to injury
(Panikashvili et al. 2001; Maccarrone et al. 2003; Marsicano
et al. 2003; Pavlopoulos et al. 2006). Blocking cannabinergic
inactivation is an avenue to promote such responses, and the
hydrolase FAAH is a primary mediator of breaking down
released endocannabinoids (Tsou et al. 1999; Cravatt et al.
2001; Egertova et al. 2003; Kathuria et al. 2003; Morozov et
al. 2004). Exploiting FAAH as a key regulatory site of
endocannabinoid signaling, we have shown that the new
generation, reversible FAAH inhibitor AM5206 modulates
the endocannabinoid system and provides protection against
excitotoxicity in vitro and in vivo. Protection was evident
with respect to all parameters measured, including histolog-
ical assessment, cytoskeletal damage, pre- and postsynaptic
markers, LDH release, and seizure scores.
KA is a seizure-inducing excitotoxin, and we found that it
elicits a pathogenic cascade in cultured hippocampal slices.
The cascade includes calpain-mediated cytoskeletal damage, a
typical concomitant loss of pre- and postsynaptic markers,
abundant pyknotic neurons within a seizure-prone brain
region and a corresponding reduction in neuronal density.
Each element of the KA-induced cascade was attenuated by
AM5206. The protection results were similar to those against
AMPA-induced excitotoxicity in hippocampal slices pro-
duced by an irreversible FAAH inhibitor as well as by an
endocannabinoid transport inhibitor (Karanian et al. 2005b).
The organotypic tissue model, in conjunction with specific
antibodies to synaptic and cytoskeletal markers, makes for a
sensitive method to evaluate neuroprotection. Neuronal
morphology and organized strata across subfields were
stably maintained for months in culture. The hippocampal
slice cultures are widely used to model various neuro-
pathologies due to their expression of similar signaling,
genetic, and cellular responses to pathogenic insults as found
in vivo (Vornov et al. 1994; Bahr 1995; Caba and Bahr
2004; Bonde et al. 2005; Karanian et al. 2005b; Ryzhikov
and Bahr 2008; Jourdi et al. 2009). The slice model of
excitotoxicity is particularly valuable for characterizing
neuroprotective modulators of the endocannabinoid system.
The cytoskeletal and synaptic protection described here
suggests that AM5206 protects against KA-induced neuronal
atrophy by reducing calpain-mediated spectrin breakdown
and preserving synaptic signaling.
The AM5206-mediated neuroprotection in the slice
model translated to protective results in an in vivo model
of excitotoxicity. KA is commonly used to induce seizures
in order to understand neurodegenerative mechanisms
(Wang et al. 2005). KA is known to elicit seizure damage
characteristic of epilepsy, and the seizure scores exhibited
in the KA-treated rats were significantly reduced by the
FAAH inhibitor. Reduced seizure severity was evident
across the seizure scoring period, providing evidence that
AM5206 has an extended influence on excitotoxic progres-
sion. Pharmacologically controlled modulation of the
endocannabinoid system through the safe targeting of
FAAH is important since complete inhibition, considering
Fig. 6 Repeated administrations
of AM5206 were assessed for
signs of toxicity in rats. Animals
in groups of four were injected i.p.
with vehicle (0 mg/kg) or
5–15 mg/kg AM5206 daily for
14 days. They were evaluated by
seizure scorers during the
2-h postinjection periods on the
last 3 days of treatment (a);
overall mean scores ± SD are
shown. Blood was subsequently
collected for measures of ALT
activity (b) and BUN levels (c) in
plasma, which are plotted as
means ± SEM
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FAAH-knockout mice for instance, was found to produce
susceptibility to spastic and proconvulsant activity (Cravatt
et al. 2001; Clement et al. 2003). Features of the excitotoxic
cascade found in the slice model were present in vivo, and
AM5206 also prevented the cytoskeletal damage and
synaptic decline measured in the rat model. The ability of
AM5206 to cross the blood–brain barrier and enhance the
protective nature of the cannabinoid system without adverse
effects demonstrates that endocannabinoid modulation is a
potential avenue to treat excitotoxic injuries, including
those stemming from seizure events.
Basal activity of the cannabinergic network in the brain
plays an important part in the maintenance of neural
connectivity and cell survival. Several studies have shown
that blocking endocannabinoid signals causes synaptic
disruption, increases excitotoxic vulnerability, and
decreases survival responses (Parmentier-Batteur et al.
2002; Marsicano et al. 2003; Khaspekov et al. 2004;
Karanian et al. 2005a). Correspondingly, enhancing endo-
cannabinoid signaling leads to improved neuronal survival
(Marsicano et al. 2003; Karanian et al. 2005b; Fernandez-
Ruiz et al. 2010; Wolf et al. 2010). Much focus has been
put on FAAH inhibition for an avenue to modulate levels of
AEA as a major component of on-demand responses
(Hwang et al. 2010). Selective inhibition of FAAH was
achieved with the new generation inhibitor AM5206, which
exhibits FAAH selectivity that approaches three orders of
magnitude as compared to its action on MAGL. AM5206’s
degree of protection against KA-induced seizures and
excitotoxic damage is comparable to that produced by the
irreversible FAAH inhibitor AM374 (Karanian et al. 2007).
It is also comparable to the excitotoxic protection produced
in vitro and in vivo by dual modulation of the endocanna-
binoid system (Karanian et al. 2005b), elicited by AM374
as well as through the inhibition of endocannabinoid
transport that has individually resulted in protective effects
(Lastres-Becker et al. 2002; Marsicano et al. 2003;
Karanian et al. 2005b). Thus, selective FAAH inhibition
may be an ideal strategy with which to protect against
consequences ascribed to excitotoxic events, including
seizures, stroke, and traumatic brain injury. Complete
understanding of the effects of enhancing endocannabinoid
signaling in the CNS and thorough safety evaluations for
select FAAH inhibitors are important future goals.
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